Vyne Therapeutics said that an inhaled formulation of its VYN201 pan-BET inhibitor significantly reduced lung fibrosis and hydroxyproline levels in a mouse model of idiopathic pulmonary fibrosis (IPF) at doses of 0.5 mg/ml and 1 mg/ml, and functional lung volume and blood oxygen saturation were significantly improved. A topical formulation of VYN201 is currently in Phase 1 clinical development for the treatment of vitiligo.
Vyne President and CEO David Domzalski commented, “The data from this well-validated preclinical model of IPF clearly demonstrates VYN201’s potential to deliver a potent anti-inflammatory and anti-fibrotic response. These data in IPF support our thesis that VYN201 has potential utility as a locally-administered therapy across a variety of immuno-inflammatory indications and further underscores the potential value of our InhiBET BET inhibitor platform.”
Read the Vyne Therapeutics press release.
